Medibio Limited (ASX: MEB)


Medibio Limited (ASX: MEB) is a digital health company that has pioneered the use of objective biometrics to assist in the diagnosis and treatment of depression and other mental health disorders. www.medibio.com.au

Medibio ASX MEB Ilumen pilot Compass Group

Medibio completes first ilumen wellbeing pilot with Compass Group

Health technology company MediBio (ASX: MEB) has completed the first of four planned pilot programs using its ilumen corporate health and wellbe...
Medibio ASX MEB WellteQ mental health

Medibio partners with Australian wellness company to develop workplace mental well-being solution

Health technology company Medibio Limited (ASX: MEB) has announced it will join forces with digital corporate wellness developer WellteQ to prov...
Medibio ASX MEB Compass Group ilumen

Medibio signs two pilot contracts with Compass Group for its ilumen product

Health technology company Medibio (ASX: MEB) has taken an assertive step towards commercialising its corporate health product called ‘ilumen’ af...
Medibio ASX MEB Rio Tinto AFL Aurecon Jacobs Joint-Venture

Medibio welcomes industry stars Rio Tinto and AFL as clients

Mental health technology company Medibio (ASX: MEB) has announced further commercial contracts with industry-leading names such as Rio Tinto (AS...
Medibio ASX MEB St John of God Health Care deal healthcare

Medibio strikes a deal with Australia’s leading Catholic healthcare provider

Dual-listed mental health technology company Medibio (ASX: MEB) has struck a potentially lucrative commercial deal with St John of God Health Ca...
Medibio ASX MEB European CE Marking accreditation for mental health platform

Medibio clinches CE Marking accreditation for mental health platform

Mental-health technology company Medibio (ASX: MEB) has received European CE Marking certification for its stress-phenotype and sleep-assessing ...

Medibio bags second clinical trial agreement with world-leading Mayo Clinic

Digital mental health company Medibio Limited (ASX: MEB) has inked a five-year clinical trial agreement with the United States’ top hospital: Ma...